The Russian Direct Investment Fund has approved the production of more than 60 million doses of Sputnik V vaccine in China. Production is scheduled to begin in May this year.
“RDIF and one of China’s leading biotech companies, Shenzhen Yuanxing Gene-tech Co. announced an agreement to produce more than 60 million doses of the world’s first registered Sputnik V coronavirus vaccine”, the Foundation said.
The volume produced will ensure the vaccination of over 30 million people. The start of commercial production is scheduled for May this year.